1 / 13

Pharmacovigilance and Drug Safety Software Market Research and Forecast Report 2022-2027

The global pharmacovigilance and drug safety software market reached a value of US$ 176.6 Million in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 265 Million by 2027 exhibiting a CAGR of 6.60% during 2022-2027.<br>More info:- https://www.imarcgroup.com/pharmacovigilance-drug-safety-software-market

21058
Download Presentation

Pharmacovigilance and Drug Safety Software Market Research and Forecast Report 2022-2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Pharmacovigilance and Drug Safety Software Market Research and Forecast Report 2022-2027 Author: Elena Anderson Marketing Manager Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group © 2022 IMARC All Rights Reserved

  2. Report DescriptionAbout IMARC Group International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

  3. Report Description and Highlights Report Description Global Pharmacovigilance and Drug Safety Software Market Research Report 2022- 2027: The latest report by IMARC Group, titled “Pharmacovigilance and Drug Safety Software Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” finds that the global pharmacovigilance and drug safety software market reached a value of US$ 176.6 Million in 2021. Pharmacovigilance (PV) and drug safety software is a management solution that enables the creation, classification, review, submission, and maintenance of PV data and adverse event reports. The process involves monitoring medical drug effects to identify and examine the unfavorable reactions of the drugs. It creates more knowledge and awareness among healthcare professionals. PV and drug safety software offers swift science-based safety decisions, ensures global regulatory compliance, integrates safety and risk management, and lowers the cost of PV procedures. As a result, the software is extensively employed by pharma and biotech companies, contract research organizations (CROs), business process outsourcing firms (BPOs), and other PV service providers. Request for a PDF sample of this report: https://www.imarcgroup.com/pharmacovigilance-drug- safety-software-market/requestsample

  4. Report Description and Highlights Report Description Global Pharmacovigilance and Drug Safety Software Market Trends: The market is primarily driven by the growing adoption of PV and drug safety software by various clinical research and outsourcing companies. The rising prevalence of chronic diseases, coupled with the increasing incidence rates of adverse drug reactions (ADRs), are also fueling the growth of the market. In addition to this, the easy adoption of the software due to the availability of cutting-edge technology is also propelling the market growth. Governments across various countries are imposing strict regulations for the commercialization of drugs. Consequently, the growing complexity related to drug safety regulations is also propelling the market growth. Furthermore, rapid digitization of clinical trials, along with the adoption of advanced technologies that improve compliance and product safety in PV and drug safety software, is creating a positive outlook for the market. Looking forward, the market is expected to reach a value of US$ 265 Million by 2027, exhibiting a CAGR of 6.60% during the forecast period (2022-2027). View Report TOC, Figures and Tables: https://www.imarcgroup.com/pharmacovigilance-drug-safety- software-market

  5. Report Description and Highlights Report Description Key Market Segmentation The research report includes the following segments: Breakup by Functionality: •Adverse Event Reporting Softwar •Drug Safety Audits Software •Issue Tracking Software •Fully Integrated Software Breakup by Delivery Mode: •On-premises •Cloud-based Breakup by End User: •Pharmaceutical and Biotechnology Companies •Contract Research Organizations •Business Process Outsourcing Firms •Others

  6. Report Description and Highlights Report Description Breakup by Region: •North America •Asia Pacific •Europe •Latin America •Middle East and Africa Competitive Landscape with Key Players: •Ab Cube •Anju Software Inc. •ArisGlobal LLC •Cognizant •Ennov Solutions Inc. •Extedo GmbH •Max Application •Oracle Corporation •Sarjen Systems Pvt Ltd •Sparta Systems Inc. (Honeywell International Inc.) •Tata Consultancy Services Limited •United BioSource LLC •Wipro Limited.

  7. Key Questions Answered in the Report Report Description 1. How has the global pharmacovigilance and drug safety software market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global pharmacovigilance and drug safety software market? What are the key regional markets? What is the breakup of the market based on the functionality? What is the breakup of the market based on the delivery mode? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global pharmacovigilance and drug safety software market and who are the key players? 10. What is the degree of competition in the industry? 2. 3. 4. 5. 6. 7. 8. 9.

  8. Report DescriptionTable of Contents 1 2 Preface Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology Executive Summary Introduction 4.1 Overview 4.2 Key Industry Trends Global Pharmacovigilance and Drug Safety Software Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 3 4 5

  9. Report DescriptionTable of Contents 6 Market Breakup by Functionality 6.1 Adverse Event Reporting Software 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Drug Safety Audits Software 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Issue Tracking Software 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Fully Integrated Software 6.4.1 Market Trends 6.4.2 Market Forecast Market Breakup by Delivery Mode 7.1 On-premises 7.1.1 Market Trends 7 Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/pharmacovigilance-drug-safety-software-market/toc

  10. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

  11. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

  12. Report Description and Highlights Report Description © 2022 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

  13. Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com

More Related